S&P 500
$5,958.38
+0.7%
+$41.45
DJI
$42,654.74
+0.8%
+$331.99
NASDAQ
$19,211.10
+0.5%
+$98.78
Bitcoin
$103,125.00
-0.6%
-$628.35
AAPL
$211.31
-0.1%
-$0.14
AMZN
$205.54
+0.2%
+$0.37
GOOG
$167.32
+1.2%
+$1.92
META
$640.11
-0.6%
-$3.77
MSFT
$453.88
+0.2%
+$0.75
NVDA
$135.20
+0.3%
+$0.38
TSLA
$349.44
+1.9%
+$6.62
Celcuity (NASDAQ: CELC)
$10.61
(0.9%)
$0.09
Price as of May 16, 2025, 3:58 p.m. ET
Celcuity Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Celcuity Company Info
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.